AuraVax and University of Houston Sign Exclusive IP Licensing Agreement
shot by IP News Shots / 6:09 pm on 04 February, 2021
AuraVax Therapeutics Inc. has signed an exclusive licensing agreement with the University of Houston for intellectual property relating to a new intranasal vaccine and STING agonist technologies. The intranasal vaccine has the potential to be used in developing immunity towards COVID-19 and other viruses.
Capricor and Johns Hopkins University Sign Licensing Deal for COVID-19 Test Platform’s IP and Know-How
shot by IP News Shots / 6:40 pm on 02 February, 2021
Capricor Therapeutics Inc. has entered into a licensing deal for the intellectual property, data and know-how of a COVID-19 serology test platform from Johns Hopkins University. Capricor will work towards the clinical development of the novel imaging-based serology test platform for COVID-19.
AuraVax and MGH Sign Exclusive Licensing Agreement for IP and Technology Rights
shot by IP News Shots / 6:06 pm on 14 January, 2021
AuraVax Therapeutics Inc. and Massachusetts General Hospital (MGH) have entered into an exclusive licensing agreement for certain intellectual property and technology rights relating to compositions and discoveries of liposomal STING agonists. The agreement will help in the development of AuraVax’s lead intranasal vaccine for COVID-19 and will also help in strengthening the platform for developing therapies to target certain other viral infections.
Xbrane Hopes to Renegotiate Existing IP Agreement Terms with Vaxiion
shot by IP News Shots / 8:55 pm on 06 January, 2021
In order to be able to expand marketing authorizations in EU and the US for its Xlucane Ranibizumab biosimilar, Xbrane Biopharma AB has reworked the terms of an IP licensing agreement previously signed with Vaxiion Therapeutics Inc. The renegotiated agreement also touches upon payment of royalties up to February 2024.
Sosei to Regain Global Rights to Muscarinic Agonist Program
shot by IP News Shots / 8:14 pm on 06 January, 2021
Sosei Group Corporation has announced that it has regained global rights to their own muscarinic agonist programs, which were licensed to Allergan Inc. After Allergan was acquired by AbbVie Inc., the acquiring company decided to return the rights due to business decisions relating to their pipeline strategy.
Your one stop source for the latest IP happenings around the world
Sign up now to avail:
Access unlimited IP news related to multiple industries and stay updated on the go. We offer summaries of the latest and most relevant IP news from around the world in less than 100 words.
Custom News Feed
If you don’t want to read an endless list of news, just select industries and news categories that you want under Your Interest section to create a personalized feed – My Feed and view news that suits your needs.
Weekly News Roundup
As a bonus, registered users will receive a Weekly roundup of Top IP news related to the opted industry and news categories.